Ipca Laboratories Faces Sluggish Trend Despite Defensive Strength
Ipca Laboratories sees a weak decline amid solid but short‑lived sales beats, thin margins, and valuation near its 5‑year average, warning defenders of hidden fragility.
3 minutes to read